Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01138150 · ClinicalTrials.gov registry record · Phase 4
Ictal and Interictal Inflammatory Markers in Migraine
A Phase 4 study, sponsored by Johns Hopkins University.
- Completed
- Registry status
- Phase 4
- Development phase
- 36
- Enrollment target
NCT01138150: Completed Phase 4 study, sponsored by Johns Hopkins University.
NCT01138150 is a Phase 4 study that has completed, run by Johns Hopkins University. The registered enrollment target is 36 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01138150, a Phase 4 study, has completed, sponsored by Johns Hopkins University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 36 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate blood levels of several proteins that may be altered in the inflammation associated with migraine headaches. These blood levels will be evaluated in individuals during an acute migraine attack and compared to their levels when pain free. The investigators study hypothesis is that the pro inflammatory proteins in the blood will be greater than the levels of these proteins when evaluated during a pain free period.
Interventions
- DRUG Placebo
- DRUG Treximet
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2009-09 |
| Est. Completion | 2013-06 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01138150
The ClinicalTrials.gov registry entry for NCT01138150 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01138150 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01138150 about?
NCT01138150 is a clinical study titled "Ictal and Interictal Inflammatory Markers in Migraine". The purpose of this study is to evaluate blood levels of several proteins that may be altered in the inflammation associated with migraine headaches. These blood levels will be evaluated in individuals during an acute migraine attack and compared to their levels when pain free. The investigators stu...
What is the current status of trial NCT01138150?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 36 participants. The study started on 2009-09. Estimated completion is 2013-06.
What interventions are being tested in trial NCT01138150?
The interventions under investigation include: Placebo (DRUG), Treximet (DRUG).
Who is sponsoring clinical trial NCT01138150?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.